Yin Qiao-xiang, Wang Heng, Pei Zhi-yong, Zhao Yu-sheng
Department of Geriatric Cardiology, Chinese General Hospital of Air Force, Beijing, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Aug;35(4):404-10. doi: 10.3881/j.issn.1000-503X.2013.04.009.
To evaluate the efficacy of cyclosporine A-nanoparticles emulsion (CsA-NP) combined with adipose tissue-derived stem cells (ASCs)transplantation therapy for acute myocardial infarction (AMI) in a miniswine model.
CsA-NP emulsion was prepared by the high-pressure homogenization method. Models were performed by coronary angioplasty for percutaneous balloon occlusion of left anterior descending artery (LAD). A total of 17 miniswines survived after AMI were divided into four groups: control group (n=5), CsA-NP group (n=4), ASCs group (n=4), and CsA-NP+ASCs group (n=4). ASCs or saline were delivered by intracoronary injection one week after AMI.Before cell transplantation and 8 weeks after cell transplantation, delayed-enhanced magnetic resonance imaging (DE-MRI) was performed to evaluate cardiac function and viability. The infarcted myocardium and implanted cells were histologically studied.
Eight weeks after treatment, the left ventricular ejection fraction (LVEF)significantly increased in the CsA-NP+ASCs group when compared with the ASCs group [(53.6 ± 2.4)% vs. (48.3 ± 1.8)%, P<0.05]; meanwhile, the infarct size significantly decreased [(6.2 ± 1.7)cm(3) vs.(7.5 ± 0.6) cm(3), P<0.05] and the thickness of the ventricular wall significantly increased (P<0.05). Histology showed that the number of surviving cells increased nearly by three times in the CsA-NP+ASCs group, and the expressions of the cardiomyocyte specific markers (cTnT and α-actin) were detected. Histological samples also showed that CsA-NP+ASCs group reduced fibrotic tissue, and down-regulated the activation of Caspase-3.
The CsA-NP+ASCs combination therapy can enhance the viability of ASCs by improving LVEF and preventing LV expansion, which may be explained that CsA-NP has the anti-apoptotic effect and can promote the survivals and proliferation of ASCs.
在小型猪模型中评估环孢素A纳米颗粒乳剂(CsA-NP)联合脂肪组织来源干细胞(ASCs)移植治疗急性心肌梗死(AMI)的疗效。
采用高压均质法制备CsA-NP乳剂。通过冠状动脉成形术对左前降支(LAD)进行经皮球囊闭塞建立模型。17只AMI后存活的小型猪分为四组:对照组(n = 5)、CsA-NP组(n = 4)、ASCs组(n = 4)和CsA-NP + ASCs组(n = 4)。AMI后1周通过冠状动脉内注射给予ASCs或生理盐水。在细胞移植前和细胞移植后8周,进行延迟增强磁共振成像(DE-MRI)以评估心脏功能和存活情况。对梗死心肌和植入细胞进行组织学研究。
治疗8周后,与ASCs组相比,CsA-NP + ASCs组左心室射血分数(LVEF)显著升高[(53.6 ± 2.4)%对(48.3 ± 1.8)%,P < 0.05];同时,梗死面积显著减小[(6.2 ± 1.7)cm³对(7.5 ± 0.6)cm³,P < 0.05],心室壁厚度显著增加(P < 0.05)。组织学显示,CsA-NP + ASCs组存活细胞数量增加近三倍,并检测到心肌细胞特异性标志物(cTnT和α-肌动蛋白)的表达。组织学样本还显示,CsA-NP + ASCs组减少了纤维化组织,并下调了Caspase-3的激活。
CsA-NP + ASCs联合治疗可通过改善LVEF和防止左心室扩张来提高ASCs的存活能力,这可能是因为CsA-NP具有抗凋亡作用,可促进ASCs的存活和增殖。